<DOC>
	<DOCNO>NCT01796951</DOCNO>
	<brief_summary>Regular aspirin use associate reduction development number different malignancy include lung cancer . The mechanism aspirin 's cancer prevention know . This study evaluate whether daily aspirin use reduce production protein name prostaglandin E2 ( PGE-2 ) , know promote cancer . Specifically , study evaluate aspirin inhibit production PGE-2 block enzyme name cycloxygenase-2 ( COX-2 ) . To accomplish goal , participant take either aspirin 325 mg daily , celecoxib 200 mg twice daily , combination various day 16-day study . Urine collect evaluate PGE-2 production 4 timepoints 16-day study .</brief_summary>
	<brief_title>Low Dose Aspirin Inhibition COX-2 Derived PGE2 Male Smokers</brief_title>
	<detailed_description />
	<mesh_term>Tobacco Use Disorder</mesh_term>
	<mesh_term>Aspirin</mesh_term>
	<mesh_term>Celecoxib</mesh_term>
	<criteria>Male gender Age ≥35 Current smoker least 10 cigarette per day history ≥10 packyears ( py ) Former smoker , quit 15 year ago history least 25 py Ability comply design study Capacity freeze urine sample participant 's residence participant desire store urine specimen manner Baseline urine PGEM &gt; 13 ng/mg creatinine Serum thromboxane &gt; 150 μg/L History aspirin use 114 day prior screen NSAID ( ibuprofen , naprosyn , meloxicam , etc ) use 17 day prior screen Inhaled glucocorticoid use 17 day prior screen Systemic glucocorticoid use 114 day prior screen History peptic ulcer disease Current recent clinically significant bleeding Allergy , intolerance contraindication aspirin NSAID use Thrombocytopenia ( platelet count &lt; 100,000 ) 30 day prior screen visit Severe hepatic insufficiency GFR &lt; 30 mL/min/1.73 m2 30 day prior screen visit History aspirin celecoxib allergy Elevated INR ( &gt; 1.5 ) 30 day prior screen visit Current diagnosis malignancy history nonskin malignancy last 5 year Current use systemic anticoagulant ( e.g. , warfarin ( Coumadin ) , enoxaparin ( Lovenox ) , Fondaparinux ( Arixtra ) , dabigatran ( Pradaxa ) ) Diagnosis COPD Intake &gt; 250 mg fish oil supplementation daily</criteria>
	<gender>Male</gender>
	<minimum_age>35 Years</minimum_age>
	<maximum_age>90 Years</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>